tbuckley/cabot-search huggingface dataset:
THE VALUE OF KOCH'S TUBERCULIN.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postmenopausal Hormone Use and Primary Prevention of Heart Disease and Stroke in Healthy Women
Journal: Annals of Internal Medicine (2000)

Summaries for Patients19 December 2000Postmenopausal Hormone Use and Primary Prevention of Heart Disease and Stroke in Healthy WomenSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-12-200012190-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Primary prevention means preventing a disease in persons with no history of the disease; secondary prevention means preventing recurrence or progression of the disease in persons who already have it. Many preliminary studies have suggested that treatment with hormones protects women from heart disease, but a recent large trial of hormone replacement therapy in women with heart disease (secondary prevention) indicated that the effects of hormone therapy on the heart may be somewhat complicated; it looked like more heart attacks and strokes occurred with short-term use of hormones, ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease.” It is in the 19 December 2000 issue of Annals of Internal Medicine (volume 133, pages 933-941). The authors are F Grodstein, JE Manson, GA Colditz, WC Willett, FE Speizer, and MJ Stampfer.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease Francine Grodstein , JoAnn E. Manson , Graham A. Colditz , Walter C. Willett , Frank E. Speizer , and Meir J. Stampfer Metrics Cited byKnowledge Resources: Finding Answers to Primary Care Questions 19 December 2000Volume 133, Issue 12Page: I-60KeywordsCardiovascular disease riskCardiovascular diseasesCardiovascular therapyEstrogensHormone replacement therapyHormonesMedical risk factorsMyocardial infarctionObservational studiesStroke ePublished: 19 December 2000 Issue Published: 19 December 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Blut, Munich
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling
Authors: Julian C. Braz, Orlando F. Bueno, Qiangrong Liang, Benjamin J. Wilkins, Yan-Shan Dai, Stephanie Parsons, Joseph Braunwart, Betty J. Glascock, Raisa Klevitsky, Thomas F. Kimball, Timothy E. Hewett, Jeffery D. Molkentin
Journal: Journal of Clinical Investigation (2003)

The MAPKs are important transducers of growth and stress stimuli in virtually all eukaryotic cell types. In the mammalian heart, MAPK signaling pathways have been hypothesized to regulate myocyte growth in response to developmental signals or physiologic and pathologic stimuli. Here we generated cardiac-specific transgenic mice expressing dominant-negative mutants of p38α, MKK3, or MKK6. Remarkably, attenuation of cardiac p38 activity produced a progressive growth response and myopathy in the heart that correlated with the degree of enzymatic inhibition. Moreover, dominant-negative p38α, MKK3, and MKK6 transgenic mice each showed enhanced cardiac hypertrophy following aortic banding, Ang II infusion, isoproterenol infusion, or phenylephrine infusion for 14 days. A mechanism underlying this enhanced-growth profile was suggested by the observation that dominant-negative p38α directly augmented nuclear factor of activated T cells (NFAT) transcriptional activity and its nuclear translocation. In vivo, NFAT-dependent luciferase reporter transgenic mice showed enhanced activation in the presence of the dominant-negative p38α transgene before and after the onset of cardiac hypertrophy. More significantly, genetic disruption of the calcineurin Aβ gene rescued hypertrophic cardiomyopathy and depressed functional capacity observed in p38-inhibited mice. Collectively, these observations indicate that reduced p38 signaling in the heart promotes myocyte growth through a mechanism involving enhanced calcineurin-NFAT signaling.
Reactive oxygen species production of neutrophils in patients with acute promyelocytic leukemia during treatment with all‐trans retinoic acid
Authors: Eiji Ohno, Eiichi Ohtsuka, Yoshio Saburi, Keiji Ono, Hiroshi Kikuchi, Masaru Nasu
Journal: American Journal of Hematology (1999)

We measured N-formyl-methionyl-leucyl-phenylalanine-induced reactive oxygen species production by neutrophils from three patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid using a luminol-enhanced chemiluminescence assay. The maximum level of reactive oxygen species production during all-trans retinoic acid treatment was 58.8 ± 2.3 × 104 (mean ± SEM) counted photons per second (cps), which was significantly higher (p < 0.0001) than that of neutrophils from healthy volunteers (13.3 ± 2.3 × 104 cps). Am. J. Hematol. 62:120–121, 1999. © 1999 Wiley-Liss, Inc.
Now: four ways to treat gonorrhea
Authors: P. Gunby
Journal: JAMA (1979)

Four drug regimens now are recommended by the Center for Disease Control (CDC), Atlanta, for treating uncomplicated gonorrhea. The new schedules represent the first major revisions in treatment recommendations since 1974. Paul J. Wiesner, MD, director of the CDC's Venereal Disease Control Division, says the principal changes involve the elevation of oral drug regimens to equal status with other therapeutic approaches. The CDC officials conferred with 12 physician "therapy consultants" before offering these "drug regimens of choice" for uncomplicated gonococcal infections in men and women: Aqueous penicillin G procaine—4.8 million units injected intramuscularly at two sites, with 1.0 g of probenecid by mouth; Tetracycline hydrochloride—0.5 g by mouth one hour before or two hours after meals (because food and some dairy products interfere with absorption), four times a day for five days to a total dose of 10.0 g; Ampicillin sodium—3.5 g, with 1 g probenecid by
Semaine des Hôpitaux: Ann Pédiat Paris
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health-Related Quality of Life—Los Angeles County, California, 1999
Journal: JAMA (2001)

The overall goals of the national health objectives for 2010 are to increase the quality and years of healthy life and eliminate health disparities in the U.S. population. To assess progress in achieving these goals, the Behavioral Risk Factor Surveillance System (BRFSS) includes a core set of four health-related quality of life (HRQOL) questions that have been used since 1993 to track adults' perceptions of their physical and mental health and level of function. Data on HRQOL have been reported nationwide and by state but typically not at the county or community level. This report summarizes findings of the 1999-2000 Los Angeles County Health Survey (LACHS) on HRQOL in the county's adult population and describes variations in HRQOL across population groups in the county. The findings have been published in a county health report and are being used by public health officials to highlight the significant disparities in HRQOL across demographic and socioeconomic populations in Los Angeles County and to guide program planning and resource allocation decisions.
JOHN REDMAN COXE (1773-1864) PROFESSOR OF MATERIA MEDICA
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Age, Sex, and Schizophrenia on the Production of Thyroid Autoantibodies
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fixed-dose combinations of drugs
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).
Authors: Shaan Dudani, Jeffrey Graham, Connor Wells, Ziad Bakouny, Sumanta K. Pal, Nazli Dizman, Frede Donskov, Camillo Porta, Guillermo de Velasco, Aaron Richard Hansen, Marco Adelmo James Iafolla, Benoit Beuselinck, Ulka N. Vaishampayan, Lori Wood, Elizabeth Chien Hern Liow, Flora Yan, Takeshi Yuasa, Georg A. Bjarnason, Toni K. Choueiri, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2019)

4577 Background: In mRCC, ipilimumab and nivolumab (ipi-nivo) is a 1L treatment option. Recent data have also shown efficacy of 1L IO-VEGF (IOVE) inhibitor combinations. Comparative data between these two strategies are limited and the efficacy of subsequent therapies remains unknown. Methods: Using the IMDC dataset, patients (pts) treated with any 1L IOVE combination were compared to those treated with ipi-nivo. Multivariable Cox regression analysis was performed to control for imbalances in IMDC risk factors. Results: 188 pts received 1L IO combination therapy: 113 treated with IOVE combinations and 75 with ipi-nivo. Baseline characteristics and IMDC risk factors were comparable between groups. When comparing IOVE combinations vs ipi-nivo, 1L response rate (RR) was 33% vs 40% (p=0.39), time to treatment failure (TTF) was 14.3 (95% CI 9.2-16.1) vs 10.2 months (95% CI 6.7-15.1, p=0.23), and median overall survival (OS) was not reached (NR) (95% CI 22.3-NR) vs NR (95% CI 35.1-NR, p=0.17). When adjusted for IMDC risk factors, the hazard ratio (HR) for TTF was 0.71 (95% CI 0.46-1.12, p=0.14) and the HR for death was 1.74 (95% CI 0.82-3.68, p=0.14). Second-line (2L) treatments were varied. In pts receiving subsequent VEGF-based therapy, 2L RR was lower in the IOVE (n=20) versus ipi-nivo (n=20) cohort (15% vs 45%; p=0.04), though 2L TTF was not significantly different (3.7 vs 5.4 months, p=0.40, n=55). The use of IO post IOVE was uncommon and 3/5 pts had PD as best response; 2/5 had PR/SD but their 1L IOVE exposure was short at &lt;3 months. Conclusions: There does not appear to be a superior 1L IO combination strategy in mRCC, as lOVE combinations and ipi-nivo have comparable 1L RR, TTF and OS. Most pts received VEGF-based therapy in the 2L. In this group, 2L RR was greater in pts who received ipi-nivo, though there was no difference in 2L TTF. [Table: see text]
Coronary microvascular endothelial dysfunction is associated with an increased risk of acute cardiovascular events during long-term follow-up Julian P. J. Halcox, Gloria Zalos, Rita Mincemoyer, William H. Schenke, Myron A. Waclwiw, Khaled R. A. Nour, Abhiram Prasad, Arshed A. Quyyumi. NIH, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)
Long-Term Outcome of Patients with Kidney Damage Due to Goodpasture Disease Who Receive Very Intensive Treatment
Journal: Annals of Internal Medicine (2001)

Summaries for Patients5 June 2001Long-Term Outcome of Patients with Kidney Damage Due to Goodpasture Disease Who Receive Very Intensive TreatmentSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-11-200106050-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?The Goodpasture syndrome (also known as anti–glomerular basement membrane, or anti-GBM, disease) causes kidney failure and, sometimes, bleeding in the lungs. It has been thought that patients who develop severe kidney failure from the Goodpasture syndrome do not usually recover their kidney function, but few large, long-term studies of this condition have been done. The Goodpasture syndrome is probably due to an autoimmune process. This means that the immune system, which should attack only foreign substances such as bacteria, attacks a person's own body tissues. Treatments for the ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Long-Term Outcome of Anti–Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression.” It is in the 5 June 2001 issue of Annals of Internal Medicine (volume 134, pages 1033-1042). The authors are JB Levy, AN Turner, AJ Rees, and CD Pusey.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLong-Term Outcome of Anti–Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression Jeremy B. Levy , A. Neil Turner , Andrew J. Rees , and Charles D. Pusey Metrics 5 June 2001Volume 134, Issue 11Page: I-10KeywordsBasement membraneBlood plasmaCyclophosphamideDrugsImmune systemKidneysMedical dialysisPatientsRenal diseasesRenal failure ePublished: 5 June 2001 Issue Published: 5 June 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The new wave in medicine: nuclear magnetic resonance
Authors: P. Gunby
Journal: JAMA (1982)

Though exploration of its clinical potential is virtually just beginning, "NMR" already has a familiar ring to many physicians. The acronym stands for nuclear magnetic resonance, one of the newest radiological forays into medical diagnosis. Focusing on the nuclei in the atoms of a single element (such as hydrogen) in biological tissue at a time, NMR can discern whether those nuclei behave normally in response to certain external forces, such as magnetism. Abnormal behavior—in comparison with normal behavior patterns still to be definitely established—may indicate a medical problem, such as ischemia or cancer. The technique, which is nonionizing and noninvasive, has been used by organic chemists, biochemists, and some physicists since shortly after World War II to identify and analyze intricate molecules of homogenous liquids or solids. Lately, though, it is being increasingly applied to medicine, generating a tremendous surge of interest. So how does it work, and why the
Thorax, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal